{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T16:24:24Z","timestamp":1769012664235,"version":"3.49.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,11,24]],"date-time":"2013-11-24T00:00:00Z","timestamp":1385251200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1007\/s00228-013-1602-9","type":"journal-article","created":{"date-parts":[[2013,11,23]],"date-time":"2013-11-23T07:20:19Z","timestamp":1385191219000},"page":"279-286","source":"Crossref","is-referenced-by-count":27,"title":["Effect of moderate liver impairment on the pharmacokinetics of opicapone"],"prefix":"10.1007","volume":"70","author":[{"given":"Jos\u00e9 Francisco","family":"Rocha","sequence":"first","affiliation":[]},{"given":"Ana","family":"Santos","sequence":"additional","affiliation":[]},{"given":"Am\u00edlcar","family":"Falc\u00e3o","sequence":"additional","affiliation":[]},{"given":"Nelson","family":"Lopes","sequence":"additional","affiliation":[]},{"given":"Teresa","family":"Nunes","sequence":"additional","affiliation":[]},{"given":"Roberto","family":"Pinto","sequence":"additional","affiliation":[]},{"given":"Patr\u00edcio","family":"Soares-da-Silva","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2013,11,24]]},"reference":[{"key":"1602_CR1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1039\/9781849737357-00083","volume-title":"Emerging drugs and targets for Parkinson\u2019s disease","author":"PN Palma","year":"2013","unstructured":"Palma PN, Laszlo K, Soares-da-Silva P (2013) Catechol-O-methyltransferase inhibitors: present problems and relevance of the new ones. In: Martinez A, Gil C (eds) Emerging drugs and targets for Parkinson\u2019s disease. The Royal Society of Chemistry, Cambridge, pp 83\u2013109"},{"issue":"8","key":"1602_CR2","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1021\/jm1001524","volume":"53","author":"LE Kiss","year":"2010","unstructured":"Kiss LE, Ferreira HS, Torrao L, Bonifacio MJ, Palma PN, Soares-da-Silva P, Learmonth DA (2010) Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase. J Med Chem 53(8):3396\u20133411","journal-title":"J Med Chem"},{"issue":"9","key":"1602_CR3","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/jcc.22926","volume":"33","author":"PN Palma","year":"2012","unstructured":"Palma PN, Bonif\u00e1cio MJ, Loureiro AI, Soares-da-Silva P (2012) Computation of the binding affinities of catechol-O-methyltransferase inhibitors: multisubstate relative free energy calculations. J Comput Chem 33(9):970\u2013986","journal-title":"J Comput Chem"},{"issue":"2","key":"1602_CR4","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1016\/j.parkreldis.2011.08.015","volume":"18","author":"MJ Bonif\u00e1cio","year":"2012","unstructured":"Bonif\u00e1cio MJ, Sutcliffe JS, Torr\u00e3o L, Wright LC, Soares-da-Silva P (2012) Brain and peripheral levodopa pharmacokinetics in the Cynomolgus monkey following administration of opicapone, a novel catechol-O-methyltransferase inhibitor. Parkinsonism Relat Disord 18(2):S125, abstract","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"1602_CR5","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1016\/j.parkreldis.2011.08.015","volume":"18","author":"MJ Bonif\u00e1cio","year":"2012","unstructured":"Bonif\u00e1cio MJ, Torr\u00e3o L, Loureiro AI, Wright LC, Soares-da-Silva P (2012) Opicapone: characterization of a novel peripheral long-acting catechol-O-methyltransferase inhibitor. Parkinsonism Relat Disord 18(2):S125, abstract","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"1602_CR6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40262-012-0024-7","volume":"52","author":"L Almeida","year":"2013","unstructured":"Almeida L, Rocha JF, Falcao A, Palma PN, Loureiro AI, Pinto R, Bonifacio MJ, Wright LC, Nunes T, Soares-da-Silva P (2013) Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor. Clin Pharmacokinet 52(2):139\u2013151","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1602_CR7","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/bcp.12081","volume":"76","author":"JF Rocha","year":"2013","unstructured":"Rocha JF, Almeida L, Falcao A, Palma PN, Loureiro AI, Pinto R, Bonifacio MJ, Wright LC, Nunes T, Soares-da-Silva P (2013) Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple-dose administration in healthy subjects. Br J Clin Pharmacol 76(5):763\u2013775","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1602_CR8","first-page":"S154","volume":"28","author":"JJ Ferreira","year":"2013","unstructured":"Ferreira JJ, Rocha JF, Falc\u00e3o A, Pinto R, Nunes T, Soares-da-Silva P (2013) Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics, motor response, and erythrocyte-COMT activity in Parkinson\u2019s patients co-administered with levodopa\/dopa-decarboxylase inhibitor. Mov Disord 28(1):S154, abstract","journal-title":"Mov Disord"},{"issue":"1","key":"1602_CR9","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1002\/mds.23847","volume":"27","author":"JJ Ferreira","year":"2012","unstructured":"Ferreira JJ, Rocha JF, Santos A, Nunes T, Soares-da-Silva P (2012) The design of a double-blind, placebo- and active-controlled, multi-national phase-III trial in patients with Parkinson\u2019s disease and end-of-dose motor fluctuations: opicapone superiority vs. placebo and non-inferiority vs. entacapone. Mov Disord 27(1):S118, abstract","journal-title":"Mov Disord"},{"issue":"1","key":"1602_CR10","first-page":"S127","volume":"27","author":"A Lees","year":"2012","unstructured":"Lees A, Costa R, Oliveira C, Lopes N, Nunes T, Soares-da-Silva P (2012) The design of a double-blind, placebo-controlled, multi-national phase-III trial in patients with Parkinson\u2019s disease and end-of-dose motor fluctuations: opicapone superiority vs. placebo. Mov Disord 27(1):S127, abstract","journal-title":"Mov Disord"},{"key":"1602_CR11","volume-title":"Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function","author":"EMEA\/CHMP","year":"2005","unstructured":"EMEA\/CHMP (2005) Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function. Committee for Medicinal Products for Human Use, European Medicines Agency, London"},{"key":"1602_CR12","volume-title":"Guidance for industry: pharmacokinetics in patients with impaired hepatic function\u2014study design, data analysis, and impact on dosing and labeling","author":"FDA\/CDER","year":"2003","unstructured":"FDA\/CDER (2003) Guidance for industry: pharmacokinetics in patients with impaired hepatic function\u2014study design, data analysis, and impact on dosing and labeling. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Silver Spring, MD"},{"key":"1602_CR13","volume-title":"Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products\u2014general considerations","author":"FDA\/CDER","year":"2000","unstructured":"FDA\/CDER (2000) Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products\u2014general considerations. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Silver Spring, MD"},{"issue":"3","key":"1602_CR14","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1476-5381.1996.tb15220.x","volume":"117","author":"MA Vieira-Coelho","year":"1996","unstructured":"Vieira-Coelho MA, Soares-da-Silva P (1996) Ontogenic aspects of liver and kidney catechol-O-methyltransferase sensitivity to tolcapone. Br J Pharmacol 117(3):516\u2013520","journal-title":"Br J Pharmacol"},{"issue":"1","key":"1602_CR15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0006-8993(99)01063-X","volume":"821","author":"MA Vieira-Coelho","year":"1999","unstructured":"Vieira-Coelho MA, Soares-da-Silva P (1999) Effects of tolcapone upon soluble and membrane-bound brain and liver catechol-O-methyltransferase. Brain Res 821(1):69\u201378","journal-title":"Brain Res"},{"issue":"23","key":"1602_CR16","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.3748\/wjg.15.2817","volume":"15","author":"G Tarantino","year":"2009","unstructured":"Tarantino G, Di Minno M, Capone D (2009) Drug-induced liver injury: is it somehow foreseeable? World J Gastroenterol 15(23):2817\u20132833","journal-title":"World J Gastroenterol"},{"key":"1602_CR17","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00228-008-0553-z","volume":"64","author":"R Verbeeck","year":"2008","unstructured":"Verbeeck R (2008) Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 64:1147\u20131161","journal-title":"Eur J Clin Pharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-013-1602-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-013-1602-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-013-1602-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,4]],"date-time":"2019-08-04T00:48:37Z","timestamp":1564879717000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-013-1602-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,24]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["1602"],"URL":"https:\/\/doi.org\/10.1007\/s00228-013-1602-9","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,24]]}}}